Claims

5

1. A method of inhibiting blood supply to a tumor, comprising the steps of:

10

(a) locating an artery which carries major blood supply to the tumor, said artery being one that is proximate to the tumor; and

15

20

25

30

(a) intra-arterially injecting into the located artery a predetermined quantity of a polyunsaturated fatty acid in the form of a solution of at least one polyunsaturated fatty acid chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid and one or more anti-angiogenic substance(s).

35

2. A method as in claim 1 including the step of causing antiangiogenic action, wherein polyunsaturated fatty acid is in the form of a lithium salt solution and wherein said predetermined quantity of the fatty acid is generally in a range of 0.5 mg to 50 gm.

10

15

20

25

30

35

40

- 3. A method as in claim 1 wherein step (b) comprises intra-arterially injecting a predetermined quantity of a polyunsaturated fatty acid in the form of a derivative of a polyunsaturated fatty acid including at least one predetermined anti-angiogenic substance to the extent of 1 to 1000 mg/kg/ body weight, said derivative of polyunsaturated fatty acid being chosen from glycerides, esters, free acids, amides, phospholipids and salts.
- 4. A method as in claim 1 wherein the polyunsaturated fatty acid is in the form of a lithium salt solution of gamma-linolenic acid and eicosapentaenoic acid/docosahexaenoic acid, including a predetermined quantity of anti-angiogenic substance chosen from Angiostatin,

 ®
 Endostatin, platelet factor-4, TNP-470, thalidomide, interleukin-12,

and metalloprotease inhibitors, and a predetermined anti-cancer drug.

- 5. A method of treating a tumor and facilitating visualization of remission of the tumor responsive to treatment, comprising
 - (a) locating an artery which carries a major portion of blood supply to

10

15

20

25

30

35

40

| Daid tallor and is story | said | tumor | and | is | adjacent to | the | tumor |
|--------------------------|------|-------|-----|----|-------------|-----|-------|
|--------------------------|------|-------|-----|----|-------------|-----|-------|

- (b) obtaining an initial radiographic image of the tumor region;
- (c) injecting into the located artery a mixture of at least
 - (i) an oily lymphographic agent as a carrier containing one or more of anti-angiogenic substance(s)
 - (ii) a lithium salt solution of at least one polyunsaturated fatty acid chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid
 - (d) obtaining second and subsequent radiographic images of the tumor region after predetermined lapses of time; and
 - (e) comparing the initial radiographic image with the second and subsequent images to assess an extent of remission of the tumor.
 - 6. A method as in claim 5 wherein step (c) comprises intra-arterially injecting a mixture containing an anti-angiogenic substance chosen

25

from Angiostatin, Endostatin, platelet factor-4, TNP-470, thalidomide, interleukin-12 causing anti-angiogenic action by inhibiting the blood supply to the tumor, wherein further the oily lymphographic agent acts as a carrier for anti-angiogenic substance(s), and also for the lithium salt solution of predetermined quantities of gamma-linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid.

- 7. A method of treating a cancerous tumor, comprising
- (a) using an oily lymphographic agent as a carrier for
- at least one polyunsaturated fatty acid chosen from a lithium salt of (i) at least one of linoleic acid, gamma-linolenic acid, dihomogamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, and cis-parinaric acid
- one predetermined anti-cancer drug, and anti-angiogenic (ii) substance(s) which are mixed with polyunsaturated fatty acids or co-valently linked to fatty acids

as a carrier.

20

25

30

35

(b) administering a predetermined quantity of selected fatty acids and

predetermined anti-angiogenic substance in the oily lymphographic agent